Hemorrhoids Treatment Market (2025 - 2033) Size, Share & Trends Analysis Report By Disease (Internal Hemorrhoids, External Hemorrhoids), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts

Hemorrhoids Treatment Market Summary

The global hemorrhoids treatment market size was estimated at USD 762.99 million in 2024 and is projected to reach USD 1,465.28 million by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The increasing prevalence of hemorrhoidal disorders is driving market growth, influenced by sedentary lifestyles, poor diets, rising obesity, and aging, which reduces tissue elasticity.

For instance, in December 2024, Journal of Disease and Global Health reported that 50% to 85% of the global population experienced hemorrhoids in their lifetime, with one-quarter of Africans over 50 affected. The study noted 3.3 million U.S. ambulatory-care visits, making hemorrhoids the fourth most common gastrointestinal disorder in outpatient settings. Mild to moderate cases were managed with fiber, hydration, and sitz baths, while severe cases used rubber band ligation, sclerotherapy, or infrared coagulation. Advanced cases required stapled hemorrhoidopexy or artery ligation, with postoperative care addressing pain, bleeding, and urinary retention. Greater awareness and diagnostic advances are driving timely interventions and treatment demand.

Technological innovations in hemorrhoid treatment methods are transforming patient care and supporting market expansion. Minimally invasive procedures, such as rubber band ligation, infrared coagulation, and laser therapy, offer faster recovery, reduced pain, and minimal complications, attracting more patients. Advanced topical formulations and oral medications improve symptom management and enhance patient adherence, while innovative combination therapies address multiple aspects of the disorder. For instance, in June 2024, Korea Biomedical Review reported that over 80% of the global population experiences hemorrhoids at some point, particularly individuals aged 45 to 65, with prevalence exceeding 50% in those over 50. The article emphasized early diagnosis, appropriate treatment strategies, and lifestyle modifications, including dietary changes and exercise, to manage and prevent complications. Clinics and hospitals increasingly implement these procedures to optimize outcomes and efficiency, reducing hospital stays and post-treatment follow-up requirements. Continuous improvements in treatment delivery and procedural techniques encourage wider adoption of these therapies, fostering growth across both developed and emerging markets globally.

Consumer demand for convenient, effective, and accessible hemorrhoid treatments is fueling market growth further. Over-the-counter ointments, suppositories, and oral supplements provide patients with practical options for self-care at home, while increasing awareness of lifestyle interventions encourages proactive symptom management. Marketing campaigns, educational initiatives, and digital platforms highlight the advantages and ease of use of modern treatments, enhancing patient engagement. Expanding distribution channels, including pharmacies, specialty clinics, and e-commerce platforms, ensure wider availability and accessibility. As patients increasingly prefer safe, minimally invasive, and home-based treatment solutions, manufacturers and healthcare providers continue to innovate, introducing new products and therapeutic options that meet evolving consumer expectations and needs.

Market Concentration & Characteristics

The hemorrhoids treatment market exhibits a moderate degree of innovation, driven by advancements in minimally invasive procedures and improved pharmacological formulations. Laser therapies, infrared coagulation, and rubber band ligation demonstrate continual procedural enhancements. Novel topical ointments and combination oral therapies enhance symptom management and patient adherence. Research focuses on faster recovery, reduced pain, and lower complication rates. Companies invest in R&D to differentiate products and services. Continuous innovation attracts healthcare providers and patients seeking effective and convenient solutions.

Market entry is moderately challenging due to high initial investment in research, clinical trials, and advanced treatment technologies. Establishing a strong distribution network and gaining physician trust requires time and resources. Existing competition from established pharmaceutical companies and specialized clinics increases entry difficulty. Compliance with international quality standards and clinical efficacy requirements adds complexity. Brand recognition and marketing capabilities are essential to capture patient attention. New entrants must offer distinct value propositions to compete effectively.

Regulatory requirements significantly influence market dynamics by ensuring product safety, efficacy, and quality. Approval processes for new drugs, devices, and minimally invasive procedures are stringent and time-consuming. Compliance with FDA, EMA, and other regional authorities impacts product launch timelines. Post-market surveillance and reporting obligations maintain patient safety standards. Regulations drive innovation towards safer and clinically validated solutions. Companies must continuously adapt evolving regulatory frameworks to maintain market access and credibility.

Substitute products, including home remedies, dietary supplements, and alternative therapies, affect market demand. Natural treatments, herbal ointments, and lifestyle interventions provide low-cost, non-invasive options. Increasing awareness of preventive care encourages self-management, reducing reliance on prescription treatments. Healthcare providers emphasize integrative approaches combining medical and home-based solutions. The availability of multiple treatment alternatives influences pricing strategies and market positioning. Manufacturers focus on differentiating products to sustain competitive advantage.

Geographical expansion drives market growth by targeting regions with rising prevalence and increasing healthcare access. North America and Europe remain mature markets with high adoption of advanced procedures. Asia Pacific and Latin America offer growth potential due to growing awareness, urbanization, and rising disposable incomes. Market players establish local partnerships, clinics, and distribution networks to capture regional opportunities. Tailoring treatments to regional preferences and accessibility improves penetration. Global expansion strategies support revenue diversification and long-term market sustainability.

Disease Insights

The internal hemorrhoids segment dominated the market with the largest revenue share of 47.12% in 2024, driven by high prevalence among adults, particularly those with sedentary lifestyles and poor dietary habits. Symptoms such as bleeding, discomfort, and prolapse prompt patients to seek medical intervention. Advanced diagnostics enable early detection and targeted treatment, while minimally invasive procedures such as rubber band ligation and infrared coagulation offer faster recovery. Oral and topical medications provide symptom relief and improve adherence. For instance, in December 2023, Scientific Reports detailed a rat internal hemorrhoid model using croton oil and exercise, revealing tissue bulging, dilated submucosal vessels, inflammatory infiltration, and increased blood perfusion, with the 1-week model closely representing clinical symptoms. Growing awareness of early treatment sustains strong market demand.

The mixed hemorrhoids segment is projected to grow at a CAGR of 7.1% over the forecast period, driven by rising recognition of complex cases requiring comprehensive management. Patients with both internal and external hemorrhoids seek treatments that address multiple symptoms simultaneously. Combination therapies and advanced procedures provide effective relief and improved outcomes. Innovations in topical and oral formulations enhance comfort and recovery. For instance, in January 2025, World Journal of Gastrointestinal Surgery published a study by Yan-Mei Huang and Dong Ouyang on mixed hemorrhoids treated with polidocanol injection combined with automatic elastic thread ligation. In a randomized trial of 100 patients, postoperative quality-of-life scores improved significantly in the treatment group compared with the control group, demonstrating substantial benefits of the combined approach. Increasing healthcare accessibility and specialized clinics promote early intervention, while patient preference for minimally invasive and convenient treatments supports segment growth globally.

Drug Class Insights

The corticosteroids segment dominated the market with the largest revenue share of 49.45% in 2024, which can be attributed to high effectiveness in reducing inflammation, swelling, and discomfort associated with hemorrhoids. Topical corticosteroid creams and suppositories provide rapid symptom relief and improve patient quality of life. Clinicians frequently recommend corticosteroids as first-line therapy for moderate to severe cases. Their proven safety and efficacy profile enhances patient confidence and adherence. For instance, in April 2025, Journal of Anus Rectum Colon published a study by Shota Takano et al., reviewing 578 patients using a combination ointment of killed Escherichia coli suspension and hydrocortisone. Among these, 430 patients (74.4%) had internal hemorrhoids, with no adverse reactions observed even over extended prescription periods, supporting the safety of long-term use. Easy availability through pharmacies and clinics ensures wide access, and continuous innovation in formulations improves potency while minimizing side effects, sustaining the dominance of corticosteroid treatments in the hemorrhoids market.

The vasoconstrictors segment is projected to grow at a CAGR of 7.1% over the forecast period, due to increased use in controlling bleeding and reducing discomfort in hemorrhoidal conditions. Products in this class offer quick relief of swelling and improve vascular tone. Rising patient preference for over-the-counter options supports segment expansion. Enhanced formulations combine vasoconstrictors with soothing agents for better symptom management. Awareness campaigns educate patients on safe and effective usage. Clinics increasingly recommend vasoconstrictors for mild to moderate cases. The segment benefits from accessibility, patient convenience, and consistent clinical results, driving the market growth over the forecast period.

Distribution Channel Insights

The hospital pharmacies segment dominated the market with the largest revenue share of 60.59% in 2024. The segment growth is attributed to the availability of advanced treatments, including prescription medications and minimally invasive procedures. Hospitals provide expert consultation and supervised administration of therapies. High patient footfall ensures consistent demand for specialized hemorrhoid medications. Integration of treatment services with patient care promotes trust and adherence. Clinicians often prefer hospital pharmacies for quality-assured products. Access to novel drugs and combination therapies strengthens market presence. Hospital pharmacies continue to lead as a reliable source for hemorrhoid treatment due to convenience and comprehensive care.

The online pharmacy segment is projected to grow at the fastest CAGR of 9.7% over the forecast period, due to increasing consumer preference for home delivery and discreet purchase of treatments. Convenience and ease of access encourage patients to explore online options. Rising digital literacy and e-commerce penetration support market expansion. Wide product availability and competitive pricing attract new users. Online platforms provide detailed product information and customer reviews to guide selection. Subscription models and repeat delivery services improve patient adherence. The growing comfort with telehealth and digital purchases drives rapid adoption of online pharmacies for hemorrhoid treatments.

Regional Insights

North America hemorrhoids treatment market held the largest revenue share of 42.73% in 2024, due to high prevalence rates among adults and increased awareness of treatment options. Advanced healthcare infrastructure ensures access to minimally invasive procedures and novel pharmacological therapies. Patients increasingly prefer convenient and effective treatment options, driving demand for prescription and OTC products. Strong presence of major pharmaceutical companies enhances availability and variety of treatments. Rising adoption of combination therapies improves patient outcomes and satisfaction. Clinical research and continuous innovation in product formulations sustain market leadership in the region.

U.S. Hemorrhoids Treatment Market Trends

Hemorrhoids treatment market in the U.S. is a major contributor to North America’s dominance due to widespread adoption of advanced treatment methods. Healthcare providers offer specialized procedures such as laser therapy and rubber band ligation for faster recovery. High patient awareness and health literacy encourage timely medical intervention. Extensive distribution networks ensure easy access to topical and oral therapies. Leading pharmaceutical companies maintain strong market presence through research and product innovation. Continuous development of patient-centric solutions supports sustained growth in the U.S. market.

Europe Hemorrhoids Treatment Market Trends

Europe holds a significant share in the hemorrhoids treatment market due to the presence of established healthcare facilities and increasing patient awareness. Minimally invasive procedures and combination drug therapies are widely available in urban centers. Rising prevalence of hemorrhoidal conditions among aging populations fuels demand. Collaboration between hospitals and pharmaceutical companies ensures wide treatment accessibility. Continuous introduction of innovative topical and oral formulations strengthens market adoption. Patient preference for safe and convenient therapies drives steady growth across the region.

UK hemorrhoids treatment market is growing with increased adoption of non-invasive and home-care treatments for hemorrhoids. Patients show preference for effective topical ointments and oral supplements for symptom relief. Clinics and pharmacies offer advanced procedural options for severe cases. Rising awareness of hemorrhoid management encourages proactive healthcare-seeking behavior. Accessibility of branded and generic treatments enhances treatment coverage. Marketing campaigns and patient education initiatives support market expansion in the UK.

Hemorrhoids treatment market in Germany maintains a strong market presence due to high healthcare standards and the availability of advanced therapies. Minimally invasive surgical procedures are widely adopted for internal and mixed hemorrhoids. Topical corticosteroids and vasoconstrictors are commonly prescribed for effective symptom control. Pharmaceutical companies continuously introduce improved formulations for better patient adherence. Growing demand for outpatient treatments reduces hospital stays and promotes market adoption. Awareness of early treatment options supports consistent growth in Germany.

France hemorrhoids treatment market is expanding with the increasing use of combination drug therapies and specialized treatment clinics. Patients actively seek professional medical guidance for hemorrhoid management. Advanced oral and topical formulations ensure rapid symptom relief and improved recovery. Hospitals and pharmacies provide a wide range of treatment options, enhancing accessibility. Rising patient preference for safe, minimally invasive therapies drives market uptake. Marketing initiatives and awareness programs strengthen patient engagement in France.

Asia-Pacific Hemorrhoids Treatment Market Trends

Asia Pacific is projected to grow at the fastest CAGR of 8.8% during the forecast period, due to the rising prevalence of hemorrhoids and growing healthcare access. Urbanization, lifestyle changes, and dietary habits contribute to increased patient cases. Expanding pharmaceutical infrastructure enables the availability of advanced procedures and treatments. Rising awareness about early intervention encourages the adoption of topical and oral therapies. Digital platforms and e-commerce support convenient access to treatments. The market growth is fueled by a combination of high unmet need and increasing disposable income across the region.

Japan hemorrhoids treatment market shows steady growth with strong adoption of minimally invasive procedures and advanced medications. Patients prefer clinically proven therapies for safe and effective symptom management. High healthcare standards ensure access to a wide range of topical and oral formulations. Collaboration between hospitals and pharmaceutical companies promotes product availability. Aging populations contribute to rising demand for hemorrhoid treatments. Awareness campaigns enhance patient engagement and timely intervention, supporting market growth.

Hemorrhoids treatment market in china is witnessing rapid market expansion due to rising prevalence, increasing urbanization, and growing health awareness. OTC and prescription treatments gain popularity among patients seeking convenient options. E-commerce platforms enhance accessibility and delivery of medications. Hospitals and clinics adopt innovative procedures for internal and mixed hemorrhoids. Rising disposable income supports adoption of advanced therapies. Patient education initiatives encourage early treatment, driving the market growth across the country.

Latin America Hemorrhoids Treatment Market Trends

Latin America demonstrates steady growth with increasing adoption of minimally invasive procedures and modern treatment options. Rising prevalence of hemorrhoids among urban populations fuels demand. Pharmacies and specialty clinics ensure product accessibility across regions. Combination therapies and improved drug formulations enhance treatment outcomes. Patient awareness campaigns promote proactive healthcare-seeking behavior. Growing investment in healthcare infrastructure supports broader adoption of treatments in the region.

Brazil hemorrhoids treatment market is a key market in Latin America with rising utilization of OTC medications and topical formulations. Patients increasingly prefer convenient home-care treatments for symptom relief. Hospitals and clinics provide advanced procedural options for severe cases. Growing awareness of hemorrhoid management encourages early intervention. Pharmaceutical companies focus on product innovation and accessibility. Market expansion is supported by rising urban population and increasing healthcare infrastructure.

Middle East & Africa Hemorrhoids Treatment Market Trends

The MEA market is growing due to increasing adoption of modern treatments and rising patient awareness. Topical ointments, oral therapies, and minimally invasive procedures gain traction among patients seeking effective solutions. Healthcare providers focus on improving accessibility and treatment outcomes. Rising disposable income enables patients to opt for advanced therapies. Clinics and pharmacies offer a range of treatment options to meet demand. Market growth is supported by lifestyle changes and increasing prevalence of hemorrhoidal conditions.

Hemorrhoids treatment market in Saudi Arabia is growing due to the rising awareness of hemorrhoid management and preference for safe, effective treatments. Patients increasingly adopt topical, oral, and combination therapies for symptom relief. Hospitals and clinics provide advanced procedural interventions for severe cases. Healthcare infrastructure expansion ensures access to modern therapies across the country. Marketing campaigns and patient education programs encourage timely treatment. The growing adoption of home-care and minimally invasive solutions supports market expansion in Saudi Arabia.

Key Hemorrhoids Treatment Company Insights

Key players in the hemorrhoids treatment market include Lupin, Cipla, Amato Pharmaceutical Products, Ltd., Church & Dwight Co., Inc., Haleon Group of Companies, Sebela Pharmaceuticals, Bayer AG, Sanofi, Abbott, and Sun Pharmaceutical Industries, Inc., each contributing through diverse portfolios and global presence. Lupin and Cipla lead with a range of generic and over-the-counter treatments, making therapies accessible to wider populations. Amato Pharmaceutical and Church & Dwight focus on specialty topical formulations and home-care products, enhancing patient convenience. Haleon and Sebela Pharmaceuticals drive adoption through innovative delivery systems and natural remedies. Bayer, Sanofi, Abbott, and Sun Pharma strengthen market presence with novel oral and topical treatments, extended-release formulations, and strategic collaborations. Collectively, these companies fuel innovation, expand distribution, and shape the global hemorrhoids treatment landscape.

Recent Developments

• In June 2025, Haleon plc completed the acquisition of the remaining 12% equity interest in its China-based OTC joint venture, Tianjin TSKF Pharmaceutical Co. Ltd (TSKF), for a total consideration of approximately USD 225 million (RMB 1,623 million).

• In March 2024, Karo Healthcare acquired the rights to the OTC hemorrhoid brand Proctosedyl from Bayer in Italy. The deal included global dossier ownership and an exclusive license for the Italian market.

• In November 2023, Servier Malaysia launched emoflon, a cortisone- and lidocaine-free rectal ointment for treating hemorrhoidal disease and related complications.

Hemorrhoids Treatment Market Report Scope

Global Hemorrhoids Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemorrhoids treatment market report based on disease, drug class, distribution channel, and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)

  • Internal Hemorrhoids

  • External Hemorrhoids

  • Mixed Hemorrhoids

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Corticosteroids

  • Local Anesthetics

  • Vasoconstrictors

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Online Pharmacy

  • Retail Pharmacy

  • Hospital Pharmacy

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait